Press Note

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPCIN

Lupin Foundation Wins IDMA Corporate Citizen Award 2019

Mumbai, January 21, 2020: Pharma major Lupin Limited (Lupin) announced that its corporate social responsibility (CSR) arm, Lupin Foundation, has won the prestigious Indian Drug Manufacturers' Association (IDMA) Corporate Citizen Award 2019, at the IDMA 58th Annual Day Celebrations held in Mumbai on January 18, 2020. Lupin was conferred this award in the CSR category 'Initiative towards Agriculture,' for its beekeeping project that has directly benefitted nearly 4000 families.

Lupin is considered a torchbearer in the Bharatpur district of Rajasthan for introducing beekeeping as a means of rural livelihood in the region. While the region is an export hub for honey today, it did not produce any honey prior to 1995. Since its introduction by Lupin, Beekeeping has become a massive programme in the district and provided employment and alternative source of income for farmers.

Lupin Foundation's support extends beyond providing training and microfinance credit to beekeepers. It has helped farmers to establish their network across markets through various state-level and national-level fairs. This enterprising project has provided a livelihood for landless and marginal farmers, and the unemployed rural youth. The honey plant established with the support of the Lupin Foundation is now the number one honey exporter in the country.

Commenting on the occasion, **Shri Sita Ram Gupta, Executive Director, Lupin Foundation** said, "It is an honour to be bestowed with this prestigious award. As a leader in the CSR space, we have always strived to give back to society and make a positive impact. This award recognises the organisation's commitment towards driving progress in society. Such recognitions encourage us to expand our CSR footprint."

For the **Beekeeping Project**, Lupin Foundation collaborated with the National Mustard Research Center (NMRC) and National Bee Board for knowledge partnership. The Horticulture department of the Rajasthan government as well as the Khadi and Village Industries Commission (KVIC). Going ahead Lupin Foundation plans to extend the beekeeping programme further and enable Rajasthan to produce more than 12 thousand metric tons of honey in near future. This award recognizes this effort.

About Indian Drug Manufacturer's Association (IDMA)

Indian Drug Manufacturers' Association (IDMA) was formed in 1961 and consists of over 1000 wholly-owned Indian large, medium and small companies under the State Boards (SB) in Gujarat, Himachal Pradesh & Uttaranchal, Haryana, Tamil Nadu, West Bengal, Madhya Pradesh, Telangana and Karnataka. IDMA plays an active role in many Government policy discussions and suggestions. Timely and effective representations to the Government authorities for quick resolutions of issues and quick response to members' queries is one of IDMA's main strengths.

IDMA recognizes excellence and achievements in various fields and gives away annual Awards such as the IDMA Quality Excellence Awards in manufacturing of APIs and Formulations, IDMA Margi Memorial Best Patent Award for best patents granted in India and abroad globally, IDMA Corporate Citizen Award to recognize and appreciate humanitarian CSR activities of its members.

Press Note

About Lupin Foundation

Lupin Foundation is a trust, NGO, independent body promoted by Lupin Ltd. Formed in 1988, decades before CSR became mandatory, showing its commitment beyond just compliance. The vision of Lupin Foundation is to see Indian villages not only economically prosperous but as centres of prosperity consciousness integrating leading corporate houses, planners, technologists and development oriented people having stewardship which is spiritual in Vision, scientific in temper and humanistic in Karma.

Please visit https://www.lupinfoundation.in/ for more information.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company by revenues (June 30, 2019, Bloomberg LTM). The Company is the 3rd largest pharmaceutical player in the US by prescriptions (IQVIA MAT September 2019); 3rd largest Indian pharmaceutical company by global revenues (June 30, 2019, Bloomberg LTM); and 6th largest company in the Indian Pharmaceutical Market (IQVIA MAT September 2019).

For the financial year ended March 31, 2019, Lupin's Consolidated sales and Net profits before exceptional items were at INR 163,694 million (USD 2.34 billion) and INR 9,466 million (USD 136 million) respectively.
For more information please visit :
https://www.lupin.com
https://www.linkedin.com/company/lupinglobal/
https://www.facebook.com/LupinWorld/
https://www.twitter.lupinglobal/

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055

For further information or queries please contact:

Arvind Bothra
Head – Investor Relations and M&A / Corporate Communications
Email – arvindbothra@lupin.com
Ph: +91-22-66408237

Manjira Sharma
GM – Corporate Communications
Email – manjirasharma@lupin.com
Ph: +91-22-66402532/9619123061